FEB 21, 2018 10:30 AM PST

Panel Discussion: Co-development of Drugs and Companion Diagnostics

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Associate-Professor, Pharmaceutical Sciences, Midwestern University
    Biography
      An Associate Professor with Midwestern University, and adjunct faculty member at Northwestern University Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she was with Cue Biotech and Caden Biosciences, companies she co-founded that focused on identifying modulators of G protein-coupled receptors (GPCRs) utilizing novel approaches (US Patent Numbers 6,559,128; 7,208,279; and 7,294,472). Her current research is on allosteric and functionally selective modulators of GPCRs with her primary receptors of interest being the chemokine receptor CCR1 and the recently deorphanized FFAR2. She is an International Editor for the British Journal of Clinical Pharmacology and recently served as a guest co-editor for a Frontiers in Endocrinology Bone Research themed issue on "Chemokines and Bone".
    • Business Development Manager at AroCell AB
      Biography
        Martin Shaw has been involved in the development, production and promotion of novel biomarker and laboratory diagnostics for many years.

        His particular interest is using his technical and scientific skills and knowledge to link research to the customer's needs.

        In the field of laboratory diagnostics, he has been involved in the development and promotion of several ground-breaking products including the first commercial assays for neonatal TSH, anti-gliadin IgA and a range of inflammatory biomarkers.

        In the drug discovery industry, Martin has worked widely with novel cell and tissue injury biomarkers and their application to toxicology and drug discovery.

        Martin has participated in industry-wide consortia on the qualification on biomarkers for use in preclinical toxicology studies and phase I clinical trials

        Martin has published several review articles on the application of biomarkers in drug discovery and he has lectured at many conferences, including twice being guest speaker at the FDA.

        Currently he is working with a novel exciting biomarker of cell proliferation - The AroCell TK 210 ELISA kit that has great potential as a biomarker of cell proliferation in preclinical drug development and clinical trials.
      • Professor and Department Chair, Chemical Engineering, Art Zafiropoulo Chair in Engineering, Affiliated Faculty, Bioengineering, Northeastern University, College of Engineering
        Biography
          Thomas J. Webster's (H index: 80, Google Scholar) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995) and in biomedical engineering from Rensselaer Polytechnic Institute (M.S., 1997; Ph.D., 2000). Prof. Webster is the current director of the Nanomedicine Laboratories (currently at 23 members) and has completed extensive studies on the use of nanophase materials in medicine. He pioneered the use of nanomaterials to increase tissue growth, inhibit infection, and decrease inflammation. He was appointed Department Chair of Chemical Engineering at Northeastern University in 2012 in which the Department recently broke the record for the fastest increase in ranking over a five year period from the U.S. News and World Report. In his 17 years in academics, Prof. Webster has graduated/supervised over 149 visiting faculty, clinical fellows, post-doctoral students, and thesis completing B.S., M.S., and Ph.D. students. To date, his lab group has generated over 13 textbooks, 68 book chapters, 376 invited presentations, at least 503 peer-reviewed literature articles and/or conference proceedings, at least 767 conference presentations, and 42 provisional or full patents. His research has led to the formation of 12 companies with 4 FDA approved nanomedicine products. He is the founding editor-in-chief of the International Journal of Nanomedicine (the first open-access, international journal in nanomedicine which has a 5-year impact factor of 5.03). Prof. Webster currently directs or co-directs several centers in the area of biomaterials: The Center for Natural and Tropical Biomaterials (Medellin, Colombia), The Center for Pico and Nanomedicine (Wenzhou China), and The International Materials Research Center (Soochow, China). He was named the Art Zafiropoulo Chair at Northeastern University for his contributions to nanomedicine in 2013. Prof. Webster has received numerous honors including but not limited to: 2012, Fellow, American Institute for Medical and Biological Engineering (AIMBE, representing the top 2% of all medical and biological engineers); 2013, Fellow, Biomedical Engineering Society; 2015, Wenzhou 580 Award; 2015, Zheijang 1000 Talent Program; 2016, International Materials Research Chinese Academy of Science Lee-Hsun Lecture Award; 2016, International College of Fellows, Biomaterials Science and Engineering; and 2016, Acta Biomaterialia Silver Award. He also served as the President of the U.S. Society For Biomaterials. He has appeared on BBC, NBC, ABC, Fox News, the Weather Channel, the Discovery Channel, and the recent special 'Year Million' TV series on National Geographic talking about the future of medicine and science.

        Abstract:

        The distinction between "complementary" and "companion" diagnostics tests confuse many physicians and healthcare professionals. Panelists Professor Thomas Webster (Northeastern University) and Dr. Martin Shaw (AroCell AB) will discuss the differences between "complementary" and "companion" diagnostics and why both are important. 


        Show Resources
        You May Also Like
        OCT 02, 2019 11:00 AM PDT
        Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
        OCT 02, 2019 11:00 AM PDT
        Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
        DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
        AUG 27, 2019 09:00 AM PDT
        C.E. CREDITS
        AUG 27, 2019 09:00 AM PDT
        DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
        SEP 05, 2019 04:00 PM CEST
        C.E. CREDITS
        SEP 05, 2019 04:00 PM CEST
        DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
        JUN 19, 2019 10:00 AM PDT
        JUN 19, 2019 10:00 AM PDT
        DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
        JUN 05, 2019 05:00 PM CEST
        C.E. CREDITS
        JUN 05, 2019 05:00 PM CEST
        DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
        MAR 20, 2019 09:00 AM PDT
        C.E. CREDITS
        MAR 20, 2019 09:00 AM PDT
        DATE:  March 20, 2019TIME:  9:00am PDT...
        Loading Comments...
        Show Resources